Convertible Note vs SAFE: The Deal Structure Question

Convertible note vs SAFE: the choice matters more than most pre-seed deal memos acknowledge. A convertible note is debt with an interest rate, a maturity date, and a balance sheet presence until it converts or gets repaid. A SAFE gives the holder equity rights in a future priced round, but carries no maturity, no interest, and no repayment obligation. Both instruments defer the valuation question. They do not defer the same risks.

For a VC analyst building the intake model for a pre-seed deal, the instrument type changes three things: dilution math, enforcement rights, and cleanup cost at Series A. This piece covers each, with a specific look at the EU market, where the default is not what you read in US-centric fundraising guides.

The debt-vs-equity split that changes your cap table model

On a spreadsheet, both instruments convert at a valuation cap or a discount on the Series A price. The convertible note adds one variable the SAFE does not: accrued interest.

A $500,000 convertible note at 5% annual interest over 24 months generates $50,000 in additional principal by the time it converts. That additional principal converts to equity at the same terms as the face value, meaning the investor ends up with roughly 10% more shares than the headline check implies. At a $5M post-money valuation cap, this difference is manageable. At a $2M cap, it concentrates ownership further.

The SAFE has no interest clock. What converts is exactly what went in, adjusted only by the cap or discount. This makes the SAFE's dilution profile simpler to model and simpler to present at IC. When three angels each hold a pre-money SAFE with a $3M cap, the math before a Series A is deterministic, assuming no additional instruments are issued afterward. When the stack grows to six instruments over 18 months, conversion sequencing requires careful attention regardless of instrument type.

One practical note: the post-money SAFE (the Y Combinator standard since 2018) calculates ownership on a fully diluted post-issuance basis, making dilution more predictable for both sides. Pre-money SAFEs issued before 2018 calculate on a pre-issuance basis, which understates dilution and creates disputes at conversion. If you encounter pre-money SAFEs in a deal's instrument stack, model them separately before the conversion table goes into the IC memo.

Why European funds still prefer convertible notes in 2026

If you source from US deal data exclusively, the numbers suggest SAFEs have won. In Q1 2026, SAFEs accounted for 93% of pre-seed rounds on Carta's platform in the US, with convertible notes representing roughly 7%.

In DACH, France, and Benelux, the picture is different. The legal frameworks in Germany, Switzerland, France, and the Netherlands are built around debt instruments. A standard SAFE does not map cleanly onto local insolvency, tax, or shareholder rights law in these jurisdictions. German civil law treats a Y Combinator SAFE differently than a formal loan agreement. The implications for priority at liquidation, VAT treatment of interest waivers, and shareholder notification requirements under German or Swiss GmbH law all add complexity that most local law firms advise against absorbing.

The practical result: most convertible loan agreements used in DACH and the Paris deal flow network run at 6-8% interest, 18-24 month maturity, a 20% conversion discount, and a valuation cap. The structure is more complex than a SAFE, but the legal certainty is higher in jurisdictions where the instrument has established precedent. Funds operating across London, Zurich, and DACH routinely work with convertible loan agreements as the pre-seed default. Founders raising in these markets should expect them.

The gap between US and EU practice has narrowed since 2022, but it has not closed. If your deal flow network includes German or Swiss companies, a working knowledge of convertible loan mechanics is not optional.

The valuation cap and discount: where the math surprises most analysts

Both instruments typically include a valuation cap, a conversion discount, or both. The cap protects early investors from full dilution at a high Series A valuation. The discount rewards them for early risk by giving access to the priced round at a lower effective price per share.

Where analysts most often miscalculate is the "whichever is lower" clause. A 20% discount on a $10M Series A gives an effective conversion price of $8M. If the valuation cap is $5M, the cap applies and the investor converts at a significantly more dilutive ratio. Most term sheets give the investor the benefit of whichever mechanism produces more shares. This clause is worth modeling both ways at intake, not only at term sheet review.

On the convertible note, the discount also applies to accrued interest. This doubles the compounding effect: a principal amount larger than the face value converts at a below-Series-A price. In deals where the note has run close to maturity, the total equity issued to seed noteholders at Series A can be materially higher than the headline check size implies. Founders who have not modeled this in advance are rarely comfortable with the outcome.

A useful shortcut: model the worst-case conversion cost at the outset of a deal, not as an afterthought. If an existing instrument stack converts at a $2M effective cap on a $12M Series A, the founding team is giving up a material slice of the round before the new investors price in. The IC memo needs to account for that.

What happens at maturity when a convertible note goes cold

A SAFE has no maturity date. It waits, indefinitely, for the triggering event. This is the SAFE's main structural advantage for founders and a meaningful enforcement limitation for investors.

A convertible note at maturity creates a decision point. If no priced round has occurred, the investor holds a matured debt instrument. They can demand repayment in cash, which most early-stage companies cannot provide. They can renegotiate and extend the note, typically at a cost: a higher discount, a lower cap, or additional interest. Or they can convert to equity at a pre-agreed formula, if the note includes a conversion-on-maturity provision.

In practice, calling the note is rarely exercised. Doing so accelerates insolvency for a company with no cash to repay, which destroys the investment. But the right exists. Sophisticated investors use maturity pressure as a negotiation lever: to accelerate a priced round, to renegotiate terms, or to obtain additional rights ahead of a stalled fundraise. Whether that leverage is a feature or a source of friction depends on the relationship and the deal context.

For an analyst reviewing a deal with existing convertible notes near maturity, the questions are concrete: when do the notes mature, who holds them, and what has the founder committed to in the event of non-conversion? A cap table with three notes maturing in the next six months is a different risk profile than a cap table with one note maturing in 24 months. The IC memo should document both scenarios.

The SAFE's edge: coverage before conviction on early deals

The SAFE was designed at Y Combinator in 2013 to give investors a fast, inexpensive instrument for pre-seed checks. The original intent still describes its best use case: a founder raising $150,000 from three angels who want to deploy quickly, without the legal overhead of a priced round or the interest clock of a convertible note.

The absence of a maturity date is the SAFE's defining feature for early deal flow. An investor can move on the basis of early signals, building coverage before conviction, and hold an instrument that does not impose a conversion deadline. If the company takes 30 months to reach a Series A, the SAFE converts then. If the company sells before a priced round, the SAFE converts on acquisition at the cap.

Legal costs are meaningful at early-stage check sizes. A standard SAFE uses a four-page template that most US-law firms close for under $2,000 in fees. A convertible note document covering interest calculation, default events, and pro-rata rights typically runs $2,500 to $5,000 at comparable firms. For a $50,000 check, the legal friction of the note amounts to 5-10% of the investment value. For a $500,000 check, it is a rounding error.

Skip the SAFE if you are investing in a jurisdiction where its legal status is unclear, if you want maturity pressure as a negotiation lever, or if the company already has a complex existing instrument stack that needs consolidation before the next priced round.

How the instrument choice lands in the IC memo

The IC memo section covering a deal's existing instruments should answer four questions: what is the total face value of outstanding notes and SAFEs, what valuation cap and discount apply to each, when do any notes mature and on what terms, and what is the pro-forma dilution at a target Series A valuation.

The pro-forma model is the most important artifact. Build a conversion table at three price scenarios: at the cap, at 2x the cap, and at a flat round matching the current headline valuation. Show what percentage of the fully diluted cap table the existing instruments represent in each scenario. A SAFE stack and a convertible note stack often look similar at the median scenario and diverge meaningfully at the extremes.

One pattern from pre-seed deal screening: founders with SAFE-heavy cap tables often have cleaner instruments but messier bookkeeping. Multiple small SAFEs issued at different caps over 18-24 months require careful sequencing at conversion. Founders who issued convertible notes often have fewer instruments but more contractual obligations to track. Neither structure is inherently cleaner. What matters is whether the founders can produce a complete and accurate instrument ledger on request. That document, or its absence, tells you more about operational readiness than the choice of instrument does.

The IC memo does not write itself. But the instrument section has a repeatable structure. Once you have the conversion table and the maturity timeline, two paragraphs cover the question: what the existing instruments cost the founding team at a likely Series A, and whether that cost is reflected in the current round's price. If it is not, flag it. That note in the IC memo saves the Series A team weeks of back-and-forth on instrument cleanup.

Book a briefing with the Accorata team to see how the deal intelligence platform models instrument stacks across your current pipeline.